Plain-English translation of NCT05954897 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a combination of three medications—lenvatinib, tislelizumab, and a chemotherapy regimen called RALOX—delivered directly into the liver to treat advanced hepatocellular carcinoma (a type of liver cancer). Researchers want to see if this treatment combination works well and is safe for patients who haven't had prior treatment for their cancer. About 29 people will participate in this study.
Advanced liver cancer is difficult to treat, and doctors are looking for more effective options. This medication combination brings together different types of cancer-fighting approaches—including immunotherapy and targeted therapy—to see if working together they might help patients live longer and healthier lives.
You likely qualify if…
You likely don't qualify if…
You would receive the medication combination as an outpatient, with the chemotherapy delivered directly into your liver through a specialized procedure. You would likely visit the hospital regularly for treatment and monitoring, with blood tests and imaging scans to check how well the treatment is working and watch for side effects. The study team will follow your progress closely to ensure the treatment is safe and effective for you.
AI-generated summary from trial data · Jul 11, 2026 · Not medical advice
China
Phase
Testing effectiveness
Sponsor
Guangdong Provincial People's Hospital
Enrollment target
~29 participants
Started
September 2023
Primary completion
January 2026
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years and older
Last updated on clinicaltrials.gov in July 2023.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Feng Shi
106 Second Zhongshan Road, Guangzhou, Guangdong
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.